NKGen Biotech Presents Phase 1/2a Data On Troculeucel In Alzheimer's Disease At CTAD Conference, Showing Biomarker Reductions And Cognitive Improvement; Highest Dose Demonstrates Safety With Potential To Delay Dementia
NKGen Biotech Presents Phase 1/2a Data On Troculeucel In Alzheimer's Disease At CTAD Conference, Showing Biomarker Reductions And Cognitive Improvement; Highest Dose Demonstrates Safety With Potential To Delay Dementia
NKGen生物科技在CTAD大會上發佈了有關Troculeucel在阿爾茨海默病中的1/2a期數據，顯示生物標誌物減少和認知改善；最高劑量證明安全，有潛力延緩癡呆症。
NKGen Biotech Presents Phase 1/2a Data On Troculeucel In Alzheimer's Disease At CTAD Conference, Showing Biomarker Reductions And Cognitive Improvement; Highest Dose Demonstrates Safety With Potential To Delay Dementia
NKGen生物科技在CTAD大會上發佈了有關Troculeucel在阿爾茨海默病中的1/2a期數據，顯示生物標誌物減少和認知改善；最高劑量證明安全，有潛力延緩癡呆症。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間